サンプル依頼リスト カート
  • English
  • Korean
  • Traditional Chinese
  • Simplified Chinese
デフォルト表紙
市場調査レポート
商品コード
1595054

組織工学による皮膚代替物の世界市場

Tissue Engineered Skin Substitutes

出版日
ページ情報
英文 89 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.82円
組織工学による皮膚代替物の世界市場
出版日: 2024年11月22日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 89 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

組織工学による皮膚代替物の世界市場は2030年までに54億米ドルに到達

2023年に31億米ドルと推定される組織工学による皮膚代替物の世界市場は、分析期間2023-2030年にCAGR 8.2%で成長し、2030年には54億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである生物学的代替物は、CAGR 8.8%を記録し、分析期間終了時には29億米ドルに達すると予想されます。合成代替品セグメントの成長率は、分析期間中CAGR 8.0％と推定されます。

米国市場は8億5,300万米ドルと推定、中国はCAGR 7.6％で成長予測

米国の組織工学による皮膚代替物市場は、2023年に8億5,300万米ドルと推定されます。世界第2位の経済大国である中国は、2023年から2030年にかけてCAGR 7.6%で推移し、2030年には8億2,250万米ドルの市場規模に達すると予測されています。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ7.6%と6.6%と予測されています。欧州では、ドイツがCAGR約6.5%で成長すると予測されています。

世界の組織工学による皮膚代替物市場- 主要動向と促進要因のまとめ

組織工学による皮膚代替物は創傷ケアにどのような革命を起こしているのか？

組織工学による皮膚代替物は、重度の火傷、慢性創傷、その他の皮膚損傷に苦しむ患者の損傷または喪失した皮膚組織を置換するために設計された高度生体材料です。これらの代替物は生体適合性のある足場、細胞、成長因子を用いて開発され、自然な皮膚の構造と機能を模倣し、より早い治癒を促し、瘢痕を減少させます。同種移植片、自家移植片、異種移植片として利用可能な組織工学による皮膚代替物は、再建外科、皮膚科、創傷管理に不可欠なソリューションを提供します。ヘルスケアシステムが、患者の予後改善と早期回復を重視する中、組織工学による皮膚代替物は従来の皮膚移植に代わる効果的な選択肢として支持を得ています。

組織工学による皮膚代替物市場の主要セグメントは？

主な製品タイプには、細胞性代替物、細胞性代替物、複合代替物があります。主にコラーゲンやその他の生体材料から作られる細胞性代替物は、熱傷治療や慢性創傷管理に広く使用されているため、大きなシェアを占めています。生きた細胞を含む細胞性代替物は、患者の皮膚と一体化して治癒を促進する能力から人気を集めています。組織工学による皮膚代替物の用途には、熱傷管理、糖尿病性潰瘍、褥瘡、再建手術が含まれるが、熱傷管理は重症例における迅速な皮膚再生が極めて重要であるため、最大セグメントを占めています。組織工学による皮膚代替物のエンドユーザーには、病院、創傷治療センター、専門クリニックなどが含まれます。病院は市場をリードしており、熱傷治療、再建手術、慢性創傷管理など、迅速な治癒と入院期間の短縮が重要な場合にこれらの代用品を使用しています。創傷治療センターでは、糖尿病性潰瘍、褥瘡、その他の治癒しない創傷の治療に代用皮膚を使用し、患者の回復を改善し、感染リスクを低減しています。さらに、専門クリニックでは、美容整形手術や再建手術にこれらの代用品を使用し、より良い審美的結果と回復時間の短縮を実現しています。

組織工学による皮膚代替物はヘルスケアにどのように応用されていますか？

病院では、組織工学による皮膚代替物は重度の火傷、深い傷、手術後の回復に使用され、より早い治癒を促し、傷跡の形成を最小限に抑えます。創傷治療センターでは、これらの代用品は糖尿病性潰瘍や褥瘡のような慢性創傷の管理に重要な役割を果たし、皮膚組織の再生や感染症の予防に役立ちます。再建外科や美容外科では、特に外傷や先天性欠損、がん術後などの場合に、皮膚代替物が審美的な回復と皮膚機能の改善をもたらします。また、これらの代用皮膚に高度な生体材料を使用することで、ドナー皮膚移植の必要性を減らし、合併症や回復時間を最小限に抑えることができます。

組織工学による皮膚代替物市場の成長を促進する要因は何か？

組織工学による皮膚代替物市場の成長は、熱傷や慢性創傷の罹患率の上昇、組織工学の進歩、より良い創傷ケアソリューションに対する需要の増加など、いくつかの要因によって牽引されています。生体工学的足場、成長因子を注入した代用品、天然組織との統合性向上などのイノベーションにより、ヘルスケア全体への応用が拡大しています。患者の転帰を改善し、回復時間を短縮し、入院期間を最小化することに重点が置かれているため、組織工学による皮膚代替物は創傷管理に重要なメリットをもたらし、需要をさらに促進しています。さらに、ヘルスケア支出の増加、高度な創傷治療に対する意識の高まり、再生医療への投資の増加が市場成長に寄与し、様々な医療現場での組織工学による皮膚代替物の採用を後押ししています。

セグメント

製品（生物学的、合成、生合成）;最終用途（急性期、慢性期）;エンドユーザー（病院、創傷治療センター、その他のエンドユーザー）

調査対象企業の例（注目の33社）

  • Amarantus Bioscience Holdings, Inc.
  • BSN medical
  • ConvaTec Group PLC
  • Integra LifeSciences Corporation
  • Kerecis
  • LifeNet Health
  • Mallinckrodt
  • Medline Industries, Inc.
  • MiMedx
  • Molnlycke Health Care AB
  • Organogenesis Inc.
  • Regenicin
  • Smith & Nephew
  • Tissue Regenix

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • その他の地域

第4章 競合

目次
Product Code: MCP22954

Global Tissue Engineered Skin Substitutes Market to Reach US$5.4 Billion by 2030

The global market for Tissue Engineered Skin Substitutes estimated at US$3.1 Billion in the year 2023, is expected to reach US$5.4 Billion by 2030, growing at a CAGR of 8.2% over the analysis period 2023-2030. Biological Substitutes, one of the segments analyzed in the report, is expected to record a 8.8% CAGR and reach US$2.9 Billion by the end of the analysis period. Growth in the Synthetic Substitutes segment is estimated at 8.0% CAGR over the analysis period.

The U.S. Market is Estimated at US$853.0 Million While China is Forecast to Grow at 7.6% CAGR

The Tissue Engineered Skin Substitutes market in the U.S. is estimated at US$853.0 Million in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$822.5 Million by the year 2030 trailing a CAGR of 7.6% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 7.6% and 6.6% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 6.5% CAGR.

Global Tissue Engineered Skin Substitutes Market - Key Trends and Drivers Summarized

How Are Tissue Engineered Skin Substitutes Revolutionizing Wound Care?

Tissue engineered skin substitutes are advanced biomaterials designed to replace damaged or lost skin tissues in patients suffering from severe burns, chronic wounds, and other skin injuries. These substitutes are developed using biocompatible scaffolds, cells, and growth factors to mimic the structure and function of natural skin, promoting faster healing and reducing scarring. Available as allogeneic, autologous, and xenogeneic grafts, tissue engineered skin substitutes provide vital solutions in reconstructive surgery, dermatology, and wound management. As healthcare systems emphasize better patient outcomes and faster recovery, tissue engineered skin substitutes have gained traction as effective alternatives to traditional skin grafts.

What Are the Key Segments in the Tissue Engineered Skin Substitutes Market?

Major product types include acellular, cellular, and composite substitutes. Acellular substitutes, made primarily from collagen or other biomaterials, hold a significant share due to their wide use in burn treatments and chronic wound management. Cellular substitutes, which contain living cells, are gaining popularity for their ability to integrate with the patient’s skin and enhance healing. Applications of tissue engineered skin substitutes cover burn management, diabetic ulcers, pressure ulcers, and reconstructive surgeries, with burn management representing the largest segment due to the critical need for rapid skin regeneration in severe cases. End-users of tissue engineered skin substitutes include hospitals, wound care centers, and specialty clinics. Hospitals lead the market, utilizing these substitutes for burn treatments, reconstructive surgeries, and chronic wound management, where rapid healing and reduced hospitalization are critical. Wound care centers use skin substitutes for treating diabetic ulcers, pressure sores, and other non-healing wounds, improving patient recovery and reducing the risk of infection. Additionally, specialty clinics employ these substitutes in cosmetic and reconstructive surgeries, ensuring better aesthetic outcomes and faster recovery times.

How Are Tissue Engineered Skin Substitutes Applied in Healthcare?

In hospitals, tissue engineered skin substitutes are used to treat severe burns, deep wounds, and post-surgical recovery, promoting faster healing and minimizing scar formation. In wound care centers, these substitutes play a critical role in managing chronic wounds like diabetic ulcers and pressure sores, where they help regenerate skin tissues and prevent infections. In reconstructive and cosmetic surgeries, skin substitutes provide aesthetic restoration and improved skin function, particularly in cases of trauma, congenital defects, and post-cancer surgeries. The use of advanced biomaterials in these substitutes also reduces the need for donor skin grafts, minimizing complications and recovery times.

What Factors Are Driving the Growth in the Tissue Engineered Skin Substitutes Market?

The growth in the Tissue Engineered Skin Substitutes market is driven by several factors, including rising incidence of burns and chronic wounds, advancements in tissue engineering, and increasing demand for better wound care solutions. Innovations like bioengineered scaffolds, growth factor-infused substitutes, and improved integration with natural tissues have expanded their applications across healthcare. The focus on improving patient outcomes, reducing recovery times, and minimizing hospital stays has further fueled demand, as tissue engineered skin substitutes offer critical benefits in wound management. Additionally, growing healthcare spending, rising awareness of advanced wound care treatments, and increased investment in regenerative medicine have contributed to market growth, encouraging the adoption of tissue engineered skin substitutes in diverse medical settings.

SCOPE OF STUDY:

The report analyzes the Tissue Engineered Skin Substitutes market in terms of US$ Thousand by the following Application; End-Use; Product, and Geographic Regions/Countries:

Segments:

Product (Biological, Synthetic, Biosynthetic); Application (Acute, Chronic); End-Use (Hospitals, Wound Care Centers, Other End-Uses)

Geographic Regions/Countries:

World; United States; Canada; Japan; China; Europe (France; Germany; Italy; United Kingdom; and Rest of Europe); Asia-Pacific; Rest of World.

Select Competitors (Total 33 Featured) -

  • Amarantus Bioscience Holdings, Inc.
  • BSN medical
  • ConvaTec Group PLC
  • Integra LifeSciences Corporation
  • Kerecis
  • LifeNet Health
  • Mallinckrodt
  • Medline Industries, Inc.
  • MiMedx
  • Molnlycke Health Care AB
  • Organogenesis Inc.
  • Regenicin
  • Smith & Nephew
  • Tissue Regenix

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • World Market Trajectories
    • Global Economic Update
    • Tissue Engineered Skin Substitutes - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Growing Use in Burn Treatment and Wound Care Spurs Market Demand
    • Advancements in Bio-Engineered Skin Solutions Drive Market Growth
    • Increasing Adoption in Diabetic Foot Ulcer Management Expands Addressable Market
    • Rising Focus on Chronic Wound Care Strengthens Business Case
    • Focus on Reducing Surgical Recovery Time Enhances Demand
    • Increasing Use of Collagen-Based and Synthetic Skin Substitutes Expands Market Opportunities
    • Advancements in 3D Bioprinting Technologies Propel Tissue Engineering Solutions
    • Growing Emphasis on Minimally Invasive Procedures Drives Adoption
    • Rising Use of Skin Substitutes in Reconstructive Surgeries Sustains Market Growth
    • Focus on Cosmetic and Aesthetic Applications Expands Market Scope
    • Increasing Focus on Developing Off-the-Shelf Skin Substitutes Generates Opportunities
    • Growing Use in Pediatric Wound Care Propels Market Expansion
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Tissue Engineered Skin Substitutes Market Analysis of Annual Sales in US$ Thousand for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 3: World 7-Year Perspective for Tissue Engineered Skin Substitutes by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2024 & 2030
    • TABLE 4: World Recent Past, Current & Future Analysis for Biological by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 5: World 7-Year Perspective for Biological by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 6: World Recent Past, Current & Future Analysis for Synthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 7: World 7-Year Perspective for Synthetic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Biosynthetic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 9: World 7-Year Perspective for Biosynthetic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 10: World Recent Past, Current & Future Analysis for Acute by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 11: World 7-Year Perspective for Acute by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 12: World Recent Past, Current & Future Analysis for Chronic by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 13: World 7-Year Perspective for Chronic by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Hospitals by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 15: World 7-Year Perspective for Hospitals by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 16: World Recent Past, Current & Future Analysis for Wound Care Centers by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 17: World 7-Year Perspective for Wound Care Centers by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030
    • TABLE 18: World Recent Past, Current & Future Analysis for Other End-Uses by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 19: World 7-Year Perspective for Other End-Uses by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 20: USA Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 21: USA 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 22: USA Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 23: USA 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 24: USA Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 25: USA 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • CANADA
    • TABLE 26: Canada Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 27: Canada 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 28: Canada Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 29: Canada 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 30: Canada Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 31: Canada 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • JAPAN
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 32: Japan Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Japan 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 34: Japan Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 35: Japan 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 36: Japan Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 37: Japan 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • CHINA
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 38: China Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 39: China 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 40: China Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 41: China 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 42: China Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 43: China 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • EUROPE
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 44: Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Thousand for Years 2023 through 2030 and % CAGR
    • TABLE 45: Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2024 & 2030
    • TABLE 46: Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 47: Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 48: Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 49: Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 50: Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 51: Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • FRANCE
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 52: France Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 53: France 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 54: France Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 55: France 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 56: France Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 57: France 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • GERMANY
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 58: Germany Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 59: Germany 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 60: Germany Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 61: Germany 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 62: Germany Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Germany 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • ITALY
    • TABLE 64: Italy Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 65: Italy 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 66: Italy Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 67: Italy 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 68: Italy Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Italy 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • UNITED KINGDOM
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 70: UK Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 71: UK 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 72: UK Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 73: UK 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 74: UK Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 75: UK 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • REST OF EUROPE
    • TABLE 76: Rest of Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 77: Rest of Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 78: Rest of Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 79: Rest of Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 80: Rest of Europe Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Rest of Europe 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • ASIA-PACIFIC
    • Tissue Engineered Skin Substitutes Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 82: Asia-Pacific Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 83: Asia-Pacific 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 84: Asia-Pacific Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 85: Asia-Pacific 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 86: Asia-Pacific Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Asia-Pacific 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030
  • REST OF WORLD
    • TABLE 88: Rest of World Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Product - Biological, Synthetic and Biosynthetic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 89: Rest of World 7-Year Perspective for Tissue Engineered Skin Substitutes by Product - Percentage Breakdown of Value Sales for Biological, Synthetic and Biosynthetic for the Years 2024 & 2030
    • TABLE 90: Rest of World Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by Application - Acute and Chronic - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 91: Rest of World 7-Year Perspective for Tissue Engineered Skin Substitutes by Application - Percentage Breakdown of Value Sales for Acute and Chronic for the Years 2024 & 2030
    • TABLE 92: Rest of World Recent Past, Current & Future Analysis for Tissue Engineered Skin Substitutes by End-Use - Hospitals, Wound Care Centers and Other End-Uses - Independent Analysis of Annual Sales in US$ Thousand for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Rest of World 7-Year Perspective for Tissue Engineered Skin Substitutes by End-Use - Percentage Breakdown of Value Sales for Hospitals, Wound Care Centers and Other End-Uses for the Years 2024 & 2030

IV. COMPETITION